Vascular risk factors as treatment target to prevent cognitive decline

Journal of Alzheimer's Disease

Volumn 32, Issue 3, 2012, Pages 733-740

  Richard, Edo ^a   Moll Van Charante, Eric P ^a   Van Gool, Willem A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cognitive decline; dementia; multi component intervention; prevention; randomized controlled trials; vascular risk factors

Indexed keywords

OMEGA 3 FATTY ACID;

ADVERSE OUTCOME; CARDIOVASCULAR RISK; DEMENTIA; DIABETES MELLITUS; EXERCISE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MEDICAL LITERATURE; MENTAL DETERIORATION; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMOKING;

EID: 84872249175     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120772     Document Type: Review

References (75)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112-2117. (Pubitemid 41797645)
2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of alzheimer's disease. Alzheimers Dement 3, 186-191. (Pubitemid 46825511)
3. Viswanathan A, Rocca WA, Tzourio C (2009) Vascular risk factors and dementia: How to move forward? Neurology 72, 368-374.
4. Breteler MM (2000) Vascular risk factors for alzheimer's disease: An epidemiologic perspective. Neurobiol Aging 21, 153-160. (Pubitemid 30387074)
5. Langa KM, Foster NL, Larson EB (2004) Mixed dementia: Emerging concepts and therapeutic implications. JAMA 292, 2901-2908. (Pubitemid 39628238)
6. Launer LJ (2002) Demonstrating the case that AD is a vascular disease: Epidemiologic evidence. Ageing Res Rev 1, 61-77. (Pubitemid 38340352)
7. Prins ND, van Dijk EJ, den HT, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2004) Cerebral white matter lesions and the risk of dementia. Arch Neurol 61, 1531-1534. (Pubitemid 39350263)
8. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of alzheimer disease The Nun Study. JAMA 277, 813-817. (Pubitemid 27111317)
9. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.
10. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-Dwelling older persons. Neurology 69, 2197-2204. (Pubitemid 350294674)
11. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P (2009) Epidemiological pathology of dementia: Attributable-Risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 6, e1000180.
12. Birks J (2006) Cholinesterase inhibitors for alzheimer's disease. Cochrane Database Syst Rev, CD005593.
13. McShane R, Areosa SA, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev, CD003154.
14. Middleton LE, Yaffe K (2009) Promising strategies for the prevention of dementia. Arch Neurol 66, 1210-1215.
15. Hachinski V (1992) Preventable senility: A call for action against the vascular dementias. Lancet 340, 645-648.
16. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van HF, van Duijn CN, Van BC, Grobbee DE (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and alzheimer's disease in The rotterdam study. Lancet 349, 151-154. (Pubitemid 27039193)
17. Launer LJ, RossGW, Petrovitch H, Masaki K, FoleyD,White LR, Havlik RJ (2000) Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging 21, 49-55. (Pubitemid 30224785)
18. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145. (Pubitemid 126512042)
19. Kennelly SP, Lawlor BA, Kenny RA (2009) Blood pressure and the risk for dementia: A double edged sword. Ageing Res Rev 8, 61-70.
20. Qiu C, Winblad B, Fratiglioni L (2005) The age-Dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4, 487-499. (Pubitemid 40982459)
21. Guo Z, Viitanen M, Fratiglioni L, Winblad B (1996) Low blood pressure and dementia in elderly people: The Kungsholmen project. BMJ 312, 805-808. (Pubitemid 26099298)
22. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ (2003) Low blood pressure and the risk of dementia in very old individuals. Neurology 61, 1667-1672. (Pubitemid 38020809)
23. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5, 64-74. (Pubitemid 41790697)
24. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154, 635-641. (Pubitemid 32888781)
25. Ott A, Stolk RP, van HF, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The rotterdam study. Neurology 53, 1937-1942.
26. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262. (Pubitemid 34438377)
27. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277-281.
28. Kivipelto M. Helkala EL. Laakso MP. Hanninen T. Hallikainen M. Alhainen K. Iivonen S. Mannermaa A. Tuomilehto J. Nissinen A. Soininen H. 2002. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-Life alzheimer disease. Ann Intern Med 137. 149-155 (Pubitemid 34827510)
29. Anstey KJ, Lipnicki DM, Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-Analysis. Am J Geriatr Psychiatry 16, 343-354.
30. Anstey KJ, Cherbuin N, Budge M,Young J (2011) Body mass index in midlife and late-Life as a risk factor for dementia: A meta-Analysis of prospective studies. Obes Rev 12, e426-e437.
31. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of alzheimer disease. Arch Intern Med 163, 1524-1528. (Pubitemid 36835095)
32. Hughes TF, Borenstein AR, Schofield E, Wu Y, Larson EB (2009) Association between late-Life body mass index and dementia: The Kame Project. Neurology 72, 1741-1746.
33. Hamer M, Chida Y (2009) Physical activity and risk of neurodegenerative disease: A systematic review of prospective evidence. Psychol Med 39, 3-11.
34. Ott A, Slooter AJ, Hofman A, van HF, Witteman JC, Van BC, van Duijn CM, Breteler MM (1998) Smoking and risk of dementia and alzheimer's disease in a populationbased cohort study: The rotterdam study. Lancet 351, 1840-1843. (Pubitemid 28279707)
35. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident alzheimer disease. Neurology 65, 545-551. (Pubitemid 41170713)
36. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hänninen T, Soininen H, Kervinen K, Kesäniemi YA, Laakso M, Kuusisto J (2006) Association of metabolic syndrome with alzheimer disease: A population-Based study. Neurology 67, 843-847. (Pubitemid 44394200)
37. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and alzheimer's disease in later life: Longitudinal, population based study. BMJ 322, 1447-1451. (Pubitemid 32575406)
38. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA (2010) A summary risk score for the prediction of alzheimer disease in elderly persons. Arch Neurol 67, 835-841.
39. Chang-Quan H, Hui W, Chao-Min W, Zheng-Rong W, Jun-Wen G, Yong-Hong L, Yan-You L, Qing-Xiu L (2011) The association of antihypertensive medication use with risk of cognitive decline and dementia: A meta-Analysis of longitudinal studies. Int J Clin Pract 65, 1295-1305.
40. Deschaintre Y, Richard F, Leys D, Pasquier F (2009) Treatment of vascular risk factors is associated with slower decline in alzheimer disease. Neurology 73, 674-680.
41. Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on alzheimer's disease prevalence. Lancet Neurol 10, 819-828.
42. Ritchie K, Carriere I, Ritchie CW, Berr C, Artero S, Ancelin ML (2010) Designing prevention programmes to reduce incidence of dementia: Prospective cohort study of modifiable risk factors. BMJ 341, c3885.
43. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E (2010) Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: A systematic review. Vasc Health Risk Manag 6, 775-785.
44. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R (1998) Prevention of dementia in randomised double-Blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352, 1347-1351. (Pubitemid 28510916)
45. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH (2002) The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162, 2046-2052. (Pubitemid 35168212)
46. (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265, 3255-3264.
47. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-Blind intervention trial. J Hypertens 21, 875-886. (Pubitemid 36677151)
48. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C (2008) Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-Blind, placebo controlled trial. Lancet Neurol 7, 683-689.
49. Prince MJ, Bird AS, Blizard RA, Mann AH (1996) Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 312, 801-805. (Pubitemid 26099297)
50. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J (2003) Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163, 1069-1075. (Pubitemid 36548935)
51. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, SullivanM, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): A randomised open-Label substudy. Lancet Neurol 10, 969-977.
52. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A,Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358, 2560-2572. (Pubitemid 351831357)
53. Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, Vanhees L (2008) Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev, CD005381.
54. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, Greenop KR, Almeida OP (2008) Effect of physical activity on cognitive function in older adults at risk for alzheimer disease: A randomized trial. JAMA 300, 1027-1037.
55. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-Risk individuals: A randomised placebo-controlled trial. Lancet 360, 7-22.
56. McGuinness B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev, CD003160.
57. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360, 1623-1630. (Pubitemid 35379733)
58. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA (2009) Vascular care in patients with alzheimer's disease with cerebrovascular lesions-A randomized clinical trial. J Am Geriatr Soc 57, 797-805.
59. Richard E, Gouw AA, Scheltens P, Van Gool WA (2010) Vascular care in patients with alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: The evaluation of vascular care in alzheimer's disease (EVA) study. Stroke 41, 554-556.
60. Strandberg TE, Pitkala KH, Berglind S, Nieminen MS, Tilvis RS (2006) Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: The Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: A randomized, controlled trial. Am Heart J 152, 585-592. (Pubitemid 44233412)
61. Richard E, Van den Heuvel E, Moll van Charante EP, Achthoven L,Vermeulen M, Bindels PJ,Van GoolWA(2009) Prevention of dementia by intensive vascular care (PreDIVA): A cluster-Randomized trial in progress. alzheimer Dis Assoc Disord 23, 198-204.
62. Andrieu S, Aboderin I, Baeyens JP, Beard J, Benetos A, Berrut G, Brainin M, Cha HB, Chen LK, Du P, Forette B, Forette F, Franco A, Fratiglioni L, Gillette-Guyonnet S, Gold G, Gomez F, Guimaraes R, Gustafson D, Khachaturian A, Luchsinger J, Mangialasche F, Mathiex-Fortunet H, Michel JP, Richard E, Schneider LS, Solomon A, Vellas B (2011) IAGG workshop: Health promotion program on prevention of late onset dementia. J Nutr Health Aging 15, 562-575.
63. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J (2006) Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-Based study. Lancet Neurol 5, 735-741. (Pubitemid 44205512)
64. Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B (2009) Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008" The Multidomain alzheimer PreventiveTrial (MAPT):Anew approach to the prevention of alzheimer's disease. Alzheimers Dement 5, 114-121.
65. Grober E, Buschke H, Crystal H, Bang S, Dresner R (1988) Screening for dementia by memory testing. Neurology 38, 900-903.
66. Brayne C, Gao L, Dewey M, Matthews FE (2006) Dementia before death in ageing societies-The promise of prevention and the reality. PLoS Med 3, 397.
67. Van Gool WA (2006) Can we prevent, delay, or shorten the course of dementia? PLoS Med 3, e430.
68. Langa KM, Larson EB, Karlawish JH, Cutler DM, Kabeto MU, Kim SY, Rosen AB (2008) Trends in the prevalence and mortality of cognitive impairment in the United States: Is there evidence of a compression of cognitive morbidity? Alzheimers Dement 4, 134-144. (Pubitemid 351373202)
69. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D (2011) The association between blood pressure and incident alzheimer disease:Asystematic reviewand meta-Analysis. Epidemiology 22, 646-659.
70. Kivipelto M, Solomon A, Ngandu T, Ahtiluoto S, Laatikainen T, Stranberg T, Tuomilehto J, SoininenH(2012) Finnish Geriatric Intervention Study To Prevent Cognitive Impairment and Disability (FINGER). 27th International Conference of alzheimer's Disease International, London, p. 138.
71. Richard E, Schmand B, Eikelenboom P,Westendorp RG, van GoolWA(2012) The alzheimer myth and biomarker research in dementia. J Alzheimers Dis 32(SUPPL3), doi: 10.3233/JAD-2012-112216.
72. Simpson RJ Jr, Mendys P (2010) The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review. J Clin Lipidol 4, 462-471.
73. Ligthart SA, Richard E, van Gool WA, Moll van Charante EP. Cardiovascular risk management in community-Dwelling elderly: Opportunities for prevention. Eur J Cardiovasc Prev Rehabil, 2011 Sep 19. [Epub ahead of print]
74. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, Kaambwa B, Banting M, Bryan S, Little P, Williams B, Hobbs FD (2010) Telemonitoring and self-management in the control of hypertension (TASMINH2): A randomised controlled trial. Lancet 376, 163-172.
75. Nolan RP, Upshur RE, Lynn H, Crichton T, Rukholm E, Stewart DE, Alter DA, Chessex C, Harvey PJ, Grace SL, Picard L, Michel I, Angus J, Corace K, Barry-Bianchi SM, Chen MH (2011) Therapeutic benefit of preventive telehealth counseling in the Community Outreach Heart Health and Risk Reduction Trial. Am J Cardiol 107, 690-696.